B222c4
PFIZi029-A
General
Cell Line |
|
hPSCreg name | PFIZi029-A |
Cite as: | PFIZi029-A (RRID:CVCL_VE77) |
Alternative name(s) |
B222c4
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
ZJSHi001-A (ZJSHi-KCNB1) Donor's gene variants: KCNB1 Donor diseases: developmental and epileptic encephalopathy, 26 PUFHi004-A (TMEM163 c.227T>C p.(Leu76Pro) iPSC) Donor's gene variants: TMEM 163 Donor diseases: Leukodystrophy PFIZi023-A (B217c8) Donor's gene variants: GPR56, GPR56 Donor diseases: Bilateral Frontoparietal Polymicrogyria CBIGi002-A (2890 (GBA W378G, heterozygous), 2890) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease |
Last update | 4th February 2021 |
User feedback | |
Provider |
|
Generator | Pfizer Limited - Pfizer (PFIZ) |
Distributors | |
External Databases |
|
BioSamples | SAMEA104491453 |
Cellosaurus | CVCL_VE77 |
Wikidata | Q54947283 |
General Information |
|
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | female |
Age of donor (at collection) | 5-9 |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA104491454 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Alternatives to consent are available? | Yes |
Alternatives to consent | |
Alternative consent approval number | |
Is there other documentation provided to the donor for consenting purposes? | No |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | NYU Institutional Review Board |
Approval number | i14-01725 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | NYU Institutional Review Board |
Approval number | i14-01725 |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
A leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
|
Age of donor (at collection) | 5-9 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Genes | |
Is reprogramming vector detectable? |
No |
Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 20 % |
CO2 Concentration | 5 % |
Medium |
mTeSR™ 1
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
||||
SSEA-4 |
Yes |
|
||||
TRA 1-60 |
Yes |
|
||||
SSEA-1 |
No |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
HIV 1 | Negative |
HIV 2 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Certificate of Analysis |
|
Is there a certificate of analysis available? |
Yes
Passage:
16
|
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46, XX modal karyotype in 20 cells showed a normal female chromosome and complement banding pattern
Passage number: 19
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.